Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1979 2
1980 2
1981 2
1982 3
1983 2
1984 7
1985 9
1986 3
1987 5
1988 2
1989 6
1990 5
1991 3
1992 3
1993 6
1994 4
1995 4
1996 5
1997 1
1998 2
1999 1
2000 1
2001 1
2002 9
2003 2
2005 4
2006 4
2007 1
2008 2
2009 2
2010 4
2011 6
2012 2
2013 4
2014 6
2015 4
2016 6
2017 5
2018 8
2019 4
2020 5
2021 6
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Di Mambro A, Arroyo-Berdugo Y, Fioretti T, Randles M, Cozzuto L, Rajeeve V, Cevenini A, Austin MJ, Esposito G, Ponomarenko J, Lucas CM, Cutillas P, Gribben J, Williams O, Calle Y, Patel B, Esposito MT. Di Mambro A, et al. Oncogene. 2023 Dec;42(50):3670-3683. doi: 10.1038/s41388-023-02840-1. Epub 2023 Oct 27. Oncogene. 2023. PMID: 37891368 Free PMC article.
KMT2A-rearranged (KMT2A-R) is an aggressive and chemo-refractory acute leukemia which mostly affects children. Transcriptomics-based characterization and chemical interrogation identified kinases as key drivers of survival and drug resistance in KMT2A-R leuke …
KMT2A-rearranged (KMT2A-R) is an aggressive and chemo-refractory acute leukemia which mostly affects children. Transcri …
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Larson RA. Larson RA. Semin Oncol. 2007 Dec;34(6 Suppl 5):S13-20. doi: 10.1053/j.seminoncol.2007.11.002. Semin Oncol. 2007. PMID: 18086342 Review.
Forodesine is the most recent novel agent, with a unique mechanism that has shown single-agent activity in relapsed and refractory T- and B-cell leukemias and cutaneous lymphomas. Although clinical experience is limited, treatment-related toxicities appear to be mild. The …
Forodesine is the most recent novel agent, with a unique mechanism that has shown single-agent activity in relapsed and refractory T- and B- …
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome.
Kurt H, Zheng L, Kantarjian HM, Tang G, Ravandi-Kashani F, Garcia-Manero G, Gong Z, Amin HM, Konoplev SN, Routbort MJ, Han X, Wang W, Medeiros LJ, Hu S. Kurt H, et al. Mod Pathol. 2018 Jul;31(7):1141-1154. doi: 10.1038/s41379-018-0014-x. Epub 2018 Feb 14. Mod Pathol. 2018. PMID: 29449681 Free article.
Twelve patients had follow-up after acquisition of the Philadelphia chromosome; all had persistent/refractory acute leukemia. Thirteen of 15 patients died a median of 3 months after the emergence of the Philadelphia chromosome. ...
Twelve patients had follow-up after acquisition of the Philadelphia chromosome; all had persistent/refractory acute leukemi …
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.
Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, Slotta-Huspenina J, Schirbel A, Hänscheid H, Kircher S, Buck AK, Götze K, Vick B, Jeremias I, Schwaiger M, Peschel C, Oostendorp R, Wester HJ, Grigoleit GU, Keller U. Habringer S, et al. Theranostics. 2018 Jan 1;8(2):369-383. doi: 10.7150/thno.21397. eCollection 2018. Theranostics. 2018. PMID: 29290814 Free PMC article.
Conclusion: Targeting CXCR4 with ERT is feasible and provides a highly efficient means to reduce refractory acute leukemia for subsequent cellular therapies. Prospective clinical trials testing the incorporation of CXCR4 targeting into conditioning reg …
Conclusion: Targeting CXCR4 with ERT is feasible and provides a highly efficient means to reduce refractory acute leukemia …
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
Nath K, Lee J, Elko TA, Levy L, Preston E, Devlin SM, Ponce DM, Lin RJ, Shaffer BC, Cho C, Politikos I, Jakubowski AA, Park JH, Rampal R, Perales MA, Tallman MS, Barker JN, Berman E, Tamari R, Stein E, Giralt SA, Gyurkocza B. Nath K, et al. Am J Hematol. 2023 Dec;98(12):1869-1876. doi: 10.1002/ajh.27084. Epub 2023 Sep 9. Am J Hematol. 2023. PMID: 37688521
Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrolled at the time of induction/reinduction therapy. ...
Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrol …
5-azacytidine in refractory acute leukemia.
Case DC Jr. Case DC Jr. Oncology. 1982;39(4):218-21. doi: 10.1159/000225641. Oncology. 1982. PMID: 6178065
11 patients (aged 23--75 years) with refractory acute leukemia were treated at the Maine Medical Center with 5-Azacytidine, 150 mg/m2/day, by continuous infusion for 5 days every 2 weeks. ...
11 patients (aged 23--75 years) with refractory acute leukemia were treated at the Maine Medical Center with 5-Azacytid …
Temozolomide and cisplatin in relapsed/refractory acute leukemia.
Seiter K, Katragadda S, Ponce D, Rasul M, Ahmed N. Seiter K, et al. J Hematol Oncol. 2009 May 22;2:21. doi: 10.1186/1756-8722-2-21. J Hematol Oncol. 2009. PMID: 19463179 Free PMC article. Clinical Trial.
We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. ...
We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fif …
The combination of clofarabine, etoposide, and cyclophosphamide shows limited efficacy as a bridge to transplant for children with refractory acute leukemia: results of a monitored prospective study.
Toporski J, Król L, Dykes J, Håkansson Y, Pronk C, Turkiewicz D. Toporski J, et al. Pediatr Hematol Oncol. 2021 Apr;38(3):216-226. doi: 10.1080/08880018.2020.1838012. Epub 2020 Nov 5. Pediatr Hematol Oncol. 2021. PMID: 33150834 Clinical Trial.
Children with refractory acute leukemia were enrolled to receive two induction courses of clofarabine, etoposide, and cyclophosphamide (CloEC). ...Infection was the most common toxicity. CloEC can induce responses in some patients with refractory ac …
Children with refractory acute leukemia were enrolled to receive two induction courses of clofarabine, etoposide, and c …
Idarubicin in refractory acute leukemia.
Fülle HH, Hellriegel KP. Fülle HH, et al. Onkologie. 1986 Jun;9(3):152-3. doi: 10.1159/000215992. Onkologie. 1986. PMID: 3528962 Free article.
Single-Arm Non-Blinded Multicenter Clinical Trial on T-Cell-Replete Haploidentical Stem Cell Transplantation Using Low-Dose Antithymocyte Globulin for Relapsed and Refractory Pediatric Acute Leukemia.
Kada A, Kikuta A, Saito AM, Kato K, Iguchi A, Yabe H, Ishida H, Hyakuna N, Takahashi Y, Nagasawa M, Hashii Y, Umeda K, Matsumoto K, Fujisaki H, Yano M, Nakazawa Y, Sano H. Kada A, et al. Kurume Med J. 2021 Oct 6;66(3):161-168. doi: 10.2739/kurumemedj.MS663004. Epub 2021 Aug 20. Kurume Med J. 2021. PMID: 34421094 Free article.
In recent years, haploidentical stem cell transplantation, involving high-dose cyclophosphamide administration post-transplanta tion, has been used, mainly in adults; however, its application is limited to removal of alloreactive T cells. Multicenter single-arm clinical tr …
In recent years, haploidentical stem cell transplantation, involving high-dose cyclophosphamide administration post-transplanta tion, has be …
158 results